Exhibit (e)(5)
BOSTON SCIENTIFIC CORPORATION
300 Boston Scientific Way
Marlborough, Massachusetts 01752
September 21, 2016
EndoChoice Holdings, Inc.
c/o Guggenheim Securities, LLC
330 Madison Avenue, 14th Floor
New York, NY 10017
| Re: | Extension of Exclusivity |
Ladies and Gentlemen:
We refer to the indication of interest between Boston Scientific Corporation and EndoChoice Holdings, Inc. dated September 1, 2016 (the “Indication of Interest”).
In consideration of the ongoing good faith discussions between the parties, this letter confirms that the exclusivity period under the Indication of Interest has been extended until 11:59 p.m. Eastern Time on September 27, 2016.
If you are in agreement with the foregoing, kindly sign this letter where indicated below and return a copy to us.
Sincerely,
| ||
BOSTON SCIENTIFIC CORPORATION
| ||
| By: | /s/ Michael J. Ryan | |
| Name: | Michael J. Ryan | |
| Title: | Director, Business Development | |
Agreed to on behalf of:
ENDOCHOICE HOLDINGS, INC.
| ||
| By: | /s/ Mark Gilreath | |
| Name: | Mark Gilreath | |
| Title: | Chief Executive Officer | |
